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Background: Dietary supplements have been widely used among the United States of America (USA) and 
the European Union (EU) population not only as a form of nutrition but also for medicinal purposes. Still, 
the legislation regulating these supplements remains unclear due to the fact that they can be considered as 
foodstuffs and/or medicinal products depending on various factors. Methods: The present review article 
intendeds to provide information concerning the variations on the definition of dietary supplements, the 
allowable substances on it, as well as the marketing and labelling requirements among the USA and the EU 
legislation. Results/Conclusions: In fact, several discrepancies can be found between regulations in the 
USA (mainly regulated by the Food and Drugs Administration) and in the EU (principally regulated by the 
Food Supplements Directive or by the Directive 2001/83/EC), and even between the different Member 
States of the EU, with the main differences observed in new products marketing requirements. 
 




1. Widespread use of dietary supplements 
An adequate and balanced nutrition is considered the key to maintain the normal body functions, prevent 
diseases, and age healthily. Nevertheless, there are several cases of malnutrition due to deficient, excessive 
or imbalanced intake of a wide range of nutrients present in food [1]. This lack of nutrition can derive from 
different origins such as medical (for instance anorexia, nausea and vomiting or gastrointestinal 
dysfunction) and/or environmental causes (poor food quality or availability, no respected meal times, etc.), 
or altered requirements (altered substrate demands in critical illness, or increased energy expenditure) [2]. 
For this kind of reasons, or even just to improve or maintain the overall health, wellness and mental 
conditions, balance the diet, perk up the appearance, boost the performance or delay the onset of age-related 
diseases, the application of dietary supplements has tremendously increased in the last decades [3,4,5,6,7]. 
Nowadays, these supplements are widely used as a form of nutrition not only by healthy individuals but 
also by patients with a variety of health issues because they tend to be perceived as natural and safe; 
nonetheless, the prevalent use remains in patient populations who are frequently hospitalized or at risk of 
hospitalization, such as users of prescription medication, patients with chronic conditions, and the elderly 
[8]. Among their various applications, the most common are weight loss [9,10], diabetes [11], dementia 
[1], cognition [12], prostatic hyperplasia [13], epilepsy [14], gastrointestinal issues [15], and sexual [16], 
bones, and articulations [17,18] performance improvement, among others. The growing interest on dietary 
supplements has led to the production and commercialization of a wide range of formulations containing 
vitamins, minerals, herbal preparations, or similar ingredients and, consequently, has facilitated their 
distribution in several points with free availability like pharmacies, health food stores, department stores, 
groceries, on the Internet, and even on the black market [7,19]. Albeit the easy access to these products 
offers obvious advantages by simplifying the buying process of effective professionally counselled 
treatments, the fact that anyone can easily access a variety of other supplements without medical 
prescription or advice can have several associated risks. Indeed, negative interactions with prescribed drugs, 
side effects, and other adverse effects have been noted, and once complementary and alternative medicine 
is not currently integrated with conventional medicine, a specific legislation for dietary supplements with 




2. Dietary supplements on the borderline between food and medicine legislation 
It is estimated that in the USA and the EU, nearly half of the population currently uses dietary supplements 
and that in Europe the prevalence of consumption is localized in the northern countries [5,23]. Still, the 
scope and definition of these supplements remains unclear, with variations among the applied legislation 
among different countries. 
Since ancient times, natural products such as plants and herbs have been used as healing agents, remaining 
the most common form of traditional medicine worldwide, and with the organic chemistry advances, the 
industry was able to prepare several synthetic medicines from natural sources, for instance acetylsalicylic 
acid [24], immunosuppressive cyclosporines [25], anthracycline antibiotics [26], or statins [27]. 
Nonetheless, most of these natural products can also be used in human diet, as source of nutrients and, in 
this perspective, dietary supplements containing this sort of constituents do not exactly fit into neither 
medicine nor food scope because pharmaceuticals are used to cure diseases or alleviate its symptoms, 
whereas foods are primarily used to prevent diseases through the supply of macro and micronutrients 
needed for good health in an optimal balance. Recently, the increased emergence of dietary supplements, 
and particularly those containing substances other that vitamins and minerals that exert both functions, on 
the market has blurred the distinction between pharmaceuticals and food, which place them in the borderline 
between food and drug legislation [6,7].  
In order to provide an easier comparison between the USA and the EU legislation regarding dietary 
supplements, the present study was conducted by a thorough survey of the principal competent authorities’ 
regulation documents (laws, regulations, directives, reports, etc.). For that purpose, we intended to provide 
a definition of dietary supplements, the allowable substances on its manufacturing, and the marketing and 
labelling requirements depending on the area of marketing and on the classification of such products as 
food or medicines.  
 
3. Definition of dietary supplements 
In the USA, dietary supplements are mainly regulated by the Food and Drug Administration (FDA) (Figure 
1) and have always been regulated as foods, with the enacting of the basic Food, Drug and Cosmetic Act 
(FD&C Act), in 1938 [7,28]. In this Act, Congress created a category of “foods for special dietary use” to 
include vitamin supplements, fortified foods or infant formula, which required a different label informing 
consumers about their special dietary properties. In 1941, the FDA proposed a new definition that was 
incorporated in Section 411 of the FD&C Act in 1976, under which special dietary uses included many 
specific functions like “supplying a vitamin, mineral, or other ingredient for use by man to supplement his 
diet by increasing the total dietary intake” [7,29,30]. Later, in order to formalise a number of regulatory 
statutes designed to ensure continued public access to a wide variety of dietary supplements and to provide 
consumers with more information about the intended use of dietary supplements, Dietary Supplement 
Health and Education Act 1994 (DSHEA) was enacted. According to DSHEA, a dietary supplement is “a 
product (other than tobacco) intended to supplement the diet that bears or contains one or more of the 
following dietary ingredients: a vitamin, a mineral, an herb or other botanical, an amino acid, a dietary 
substance for use by man to supplement the diet by increasing the total dietary intake, or a concentrate, 
metabolite, constituent, extract, or combination of any of the aforementioned ingredients; it is deemed to 
be food, except for purposes of the drug definition”. However, despite the modifications introduced by this 
Act, it did not change the fact that dietary supplements are classified as a category of foods [7,31]. Thus, 
hitherto the definition of this kind of supplements was considered by the Congress for three distinct 
occasions: in 1938, in 1976, and in 1994, and on each one the conclusion was that they were a subset of 
foods. Notwithstanding, the scope of these supplements have been submitted to these reviews due to the 
fact that some of these products could be considered drugs if their labelling suggested that they could be 
used for “diagnosis, cure, mitigation, treatment, or prevention of disease”, which is how drugs are defined 
in Section 201 (g) of the FD&C Act [7,32]. 
On the other hand, in the EU (Figure 2), the European Food Safety Authority (EFSA) was set up in January 
2002 as an independent source of scientific advice that produces opinions to be used by the European 
Commission (EC) that adopt legislation concerning dietary supplements; EFSA works, then, in close 
collaboration with national authorities and in open consultation with its stakeholders [7,33]. Moreover, and 
with special relevance for companies in this sector, EFSA contributed in the evaluation of proposals for the 
addition of vitamins and minerals to the Food Supplements Directive (FSD), Directive 2002/46/EC, which 
states that food supplements are "foodstuffs the purpose of which is to supplement the normal diet and 
which are concentrated sources of nutrients or other substances with a nutritional or physiological function, 
alone or in combination, marketed in dose form, namely forms such as capsules, pastilles, tablets, pills and 
other similar forms, sachets of powder, ampoules of liquids, drop dispensing bottles, and other similar forms 
of liquids and powders designed to be taken in measured small unit quantities" [7,34]. Dietary supplements 
containing herbal medicinal products are regulated by the Directive 2001/83/EC, which regulates the 
medicinal products for human use and by the Traditional Herbal Medicinal Products (THMP) Directive 
2004/24/EC that emerged to amend Directive 2001/83/EC regarding to the marketing of THMP on the EU. 
The Directive 2001/83/EC provides legal definitions for herbal medicinal products, herbal substances, and 
herbal preparations. Accordingly, a herbal medicinal product is “any medicinal product, exclusively 
containing as active ingredients one or more herbal substances or one or more herbal preparations, or one 
or more such herbal substances in combination with one or more such herbal preparations”; on the other 
hand, herbal substances are “all mainly whole, fragmented or cut plants, plant parts, algae, fungi, lichen in 
an unprocessed, usually dried form, but sometimes fresh, and also certain exudates that have not been 
subjected to a specific treatment”; while herbal preparations  are “preparations obtained by subjecting 
herbal substances to treatments such as extraction, distillation, expression, fractionation, purification, 
concentration or fermentation” that include “comminuted or powdered herbal substances, tinctures, 
extracts, essential oils, expressed juices and processed exudates” [6,7,28,35]. 
 
4. Marketing requirements for dietary supplements 
In the USA, according to DSHEA, dietary supplements are considered as a category of food, which put 
them under different regulations than drugs. As such, they must be labelled as food and “be intended for 
ingestion, they must not be represented for use as conventional food or as a sole item of a meal or of the 
diet and cannot be approved or authorized for investigation as new drugs, antibiotics, or biologics, unless 
they were marketed as food or dietary supplements before such approval or authorisation” [7,31]. The 
Office of Nutritional Products, Labelling, and Dietary Supplements is the principal office responsible for 
regulation of these products at the FDA, that regulates the marketing of dietary supplements and, therefore, 
can either refuse to allow new ingredients into or remove existing ingredients from the market for safety 
reasons [7]. Nevertheless, FDA’s authority to monitor structure/function claims of dietary supplements 
remains limited by law and has, currently, three main requirements to help ensure that such claims are 
truthful and not misleading: “substantiation to support the claims, which manufacturers must possess but 
need not submit to FDA; notification to FDA of claims within 30 days of first marketing the supplement 
with the claim; and a required disclaimer on supplement labels” [7,36]. Although manufacturers are not 
required to perform clinical trials to test new ingredients or supplements, FDA can stop a company from 
marketing a dietary supplement if proven that the product is ineffective or unsafe. In order to ensure the 
quality of supplements, the conditions of preparation, packaging, and storage are issued by FDA through 
Good Manufacturing Practices regulations, which are primarily concerned with safety and sanitation rather 
than quality [7,37]. The fact that DSHEA does not impose safety testing or approval of dietary supplements 
result in a lack of information to FDA that do not possess a comprehensive list of dietary supplements on 
the market; still, manufacturers must ensure that their products are safe, that they can, by evidence, 
substantiate structure/function claims, and that product labels are truthful and not misleading. To ensure 
the safety of supplements marketed in the USA, FDA monitors adverse event reports and consumer 
complaints, search in the Internet for products that are not in agreement with regulations, conduct onsite 
inspections of manufacturers’ facilities or imported shipments, and reviews new dietary ingredient 
notifications. This authority do not survey dietary supplements sold on retail establishments but it does 
conduct limited surveillance of products sold on the Internet [7,31,38] (Figure 3). 
In the EU, according to FSD, the fact that dietary supplements are subjected to different regulations in the 
various Member States “may impede their free movement, create unequal conditions of competition, and 
thus have a direct impact on the functioning of the internal market”, which explains the need to “adopt 
Community rules on those products marketed as foodstuffs” [7,34]. Anyway, a high level of protection for 
consumers and a facilitated choice must be ensured by putting on to the market safe products that bear 
adequate and appropriate labelling [7,34]. Additional requirements to ensure the quality of medicinal 
products can be found in Directive 2003/63/EC, which amends Directive 2001/83/EC. This Directive 
contains details of the scientific and technical requirements regarding to the marketing authorisation 
application dossier. Importantly, the unique aspects of herbal medicinal products quality are acknowledged 
in the preamble of this Directive that states that “herbal medicinal products differ substantially from 
conventional medicinal products in so far as they are intrinsically associated with the very particular notion 
of herbal substances and herbal preparations” and also refers that “it is therefore appropriate to determine 
specific requirements in respect of these products with regard to the standardised marketing authorisation 
requirements” [6,7,40]. In 2004, the Directive 2004/24/EC attempted to (i) facilitate the registration of 
certain traditional herbal medicinal products, suggesting that “there should be the possibility of establishing 
a Community list of herbal substances that fulfill certain criteria, such as having been in medicinal use for 
a sufficiently long time, and hence are considered not to be harmful under normal conditions of use”; and 
(ii) enhance harmonisation, proposing that “Member States should recognise registrations of traditional 
herbal medicinal products granted by another Member State based on Community herbal monographs or 
consisting of substances, preparations or combinations thereof contained in a list to be established”, and 
with respect to other products “Member States should take due account of such registrations” [7,41]. Thus, 
in the amended Directive 2001/83/EC, a simplified registration procedure is established for these 
supplements which fulfill criteria such as (i) having indications exclusively appropriate to THMP, being 
intended and designed for use without the supervision of a medical practitioner for diagnostic purposes or 
for prescription or monitoring of treatment;  (ii) being exclusively for administration in accordance with a 
specified strength and posology; (iii) being an oral, external an/or inhalation preparation; (iv) having been 
in medicinal use throughout a period of at least 30 years preceding the date of the application, including at 
least 15 years within the Community; and (v) proving to not be harmful in the specified conditions of use, 
with pharmacological effects or efficacy plausible on the basis of long-standing use and experience. 
Moreover, the amended Directive states that the applicant and registration holder shall be established in the 
Community and submit an application to the competent authority of the concerned Member State in order 
to obtain traditional-use registration [7,41]. Nevertheless, the fact that the European Medicines Agency 
does not have a role in the registration of THMP means that applications for registration have to be 
submitted in each Member State where the product is to be marketed and are handled by the respective 
competent authority. In this context, the Court of Justice has concluded on several occasions that the 
differences between the classification of products as foodstuffs or medicinal products in the different 
Member States will persist as long as there is no more complete harmonization of the measures required to 
ensure health protection. Thus, a product classified as foodstuff in another Member State can, at the same 
time, be marketed as medicinal product in the importation Member State, if it shows the characteristics of 
such a product. In cases where a product fulfills the definition of food supplement (as laid down in FSD) 
but, simultaneously falls within one of the definitions of medicinal product (contained in the Directive 
2001/83/EC), the provisions of the legislation applicable to medicinal products shall apply [7,39]. When it 
regards to medicinal products, the Member States competent authorities grant marketing authorisations for 
medicinal products placed on their markets, except for medicinal products which are authorized under 
Regulation (EC) 726/2004. In cases where national authorisations in more than one Member State are 
required for the same medicinal product and the marketing authorisation holder has obtained a marketing 
authorisation in a Member State, this latest must submit an application in the concerned Member State using 
the procedure of mutual recognition. Then, the concerned Member States should recognize the marketing 
authorisation already granted by the reference Member State and, therefore, authorize the marketing of the 
product on their national territory. On the contrary, if there is no marketing authorisation in the Union for 
a given medicinal product, the applicant can submit an application in all the Member States where it intends 
to obtain a marketing authorisation at the same time, making use of a decentralised procedure, and choose 
one of them as reference Member State. The marketing authorisation should then be granted in agreement 
with the decision taken by the reference Member State and the concerned Member State taking into account 
the assessment report prepared by the reference Member State and any comments made by the concerned 
Member State. In order to obtain a Union authorisation, an application must be submitted to the European 
Medicines Agency (EMA) and its scientific evaluation is carried out within the Committee for Medicinal 
Products for Human Use of the EMA; a scientific opinion is then prepared and sent to the European 
Commission which drafts a Decision. This Decision is adopted by the Commission after consulting the 
Member States through the relevant Standing Committee, and the authorisation is granted. In any cases, the 
marketing authorisation must contain the summary of product characteristics in accordance to Article 11 of 
Directive 2001/83/EC [7,34]. With the exception of the products having different therapeutic indications in 
national (decentralised/mutual recognition) and central marketing authorisations, the co-existence of both 
provided by the Communication is not allowed. Indeed, if the product falls under the optional scope of the 
centralised procedure (Article 3(2) of Regulation (EC) 726/2004), there is a possibility of choice of using 
either centralised or national procedure for the same product, but it does not allow the simultaneous co-
existence of both marketing authorizations. Thus, if a central marketing authorization has been issued, there 
is no place for an additional scientific evaluation and regulation decision for the same product. According 
to Directive 2001/83/EC, “any additional strengths, pharmaceutical forms, administration routes, 
presentations, as well as any variations and extensions” shall also be granted an authorization or be included 
in the initial marketing authorisation and all of these authorisations shall be considered as belonging to the 
same global marketing authorisation. 
On the contrary, dietary supplements considered as foodstuffs should comply with FSD and Regulation 
(EC) 1924/2006 on nutrition and health claims made on foods because they do not fulfill the definition of 
medicinal products but they comply with applicable food law. In this perspective, Member States shall 
ensure that food supplements only may be marketed within the Community if they comply with the rules 
laid down in the FSD. In agreement with this Directive, only vitamins and minerals listed in Annex I, in 
the forms listed in Annex II, may be used to manufacture food supplements, and the purity criteria for these 
substances shall be adopted by the Commission. Apart from the vitamins and minerals listed in Annex I or 
forms listed in Annex II, Member States may allow in their territory the use of such substances, provided 
that it “is used in one or more food supplements marketed in the Community on the date of entry into force 
of this Directive” or the EFSA “has not given an unfavorable opinion in respect of the use of that substance, 
or its use in that form, in the manufacture of food supplements, on the basis of a dossier supporting use of 
the substance in question to be submitted to the Commission by the Member State” [7,34]. Since May 2011, 
all unlicensed herbal medicinal products must either be marketed as medicines, or they must be removed 
from the market. They could be launched correctly labelled as food supplements, carrying no claims unless 
they have been approved according to the Nutrition and Health Claims Regulation. However, the 
classification of some dietary supplements as food products has raised some concerns due to the fact that 
the food law is not regulated as strictly as the drug law which contains additional regulatory provisions for 
protection of the consumer’s health; and also because it is necessary to disclose the factual therapeutic 
properties of medicinal plants in form of disease related indications and not in form of masked health-
related claims [7,42] (Figure 3).  
 
5. Allowable substances on dietary supplements 
In the USA, with the passage of DSHEA, a new law requiring pre-market safety notification for new dietary 
supplements ingredients became necessary and, this pre-market concept comprises two different categories: 
ingredients in the market before October 15, 1994, which are considered old dietary ingredients and 
presumed to be safe; and ingredients marketed after October 15, 1994 that are considered new dietary 
ingredients and, thus, require FDA pre-market review of safety [7,31]. In a general way, a dietary 
supplement is considered safe until proven unsafe, and as can be read in FD&C Act, amended by DSHEA, 
a dietary supplement or ingredient is considered unsafe if (i) it “presents a significant or unreasonable risk 
of illness or injury under conditions of use recommended or suggested in labelling, or if no conditions of 
use are suggested or recommended in the labelling, under ordinary conditions of use”; (ii) it “is a new 
dietary ingredient for which there is inadequate information to provide reasonable assurance that such 
ingredient does not present a significant or unreasonable risk of illness or injury; (iii) “the Secretary declares 
to pose an imminent hazard to public health or safety, except that the authority to make such declaration 
shall not be delegated and the Secretary shall promptly after such a declaration initiate a proceeding in 
accordance with sections 554 and 556 of title 5 to affirm or withdraw the declaration; or (iv) it “is or 
contains a dietary ingredient that renders it adulterated under the conditions of use recommended or 
suggested in the labelling of such dietary supplement”. If a dietary ingredient is considered safe by 
respecting the referred requirements, it can thus be introduced in dietary supplements to be marketed 
[7,31,38]. 
In the EU, specific rules on vitamins and minerals in food supplements were introduced by the FSD; Annex 
II is a list of permitted vitamin or mineral preparations that may be added for specific nutritional purposes 
in food supplements. In order to include additional substances, it has latter been amended by the 
Commission Directive 2006/37/EC, the Commission Regulation (EC) 1170/2009, the Commission 
Regulation (EU) 1161/2011, the Commission Regulation (EU) 119/2014 and the Commission Regulation 
(EU) 2015/414. The trade of products containing vitamins and minerals not listed in Annex II has been 
prohibited from the 1st of August 2005 [7,43]. Although FSD calls for establishment of harmonized 
minimum and maximum dosage amounts through the Standing Committee procedures and lays down the 
criteria for their setting, this has yet to be done and remains a competence of EU Member States that are 
also responsible for the rules regulating substances other than vitamins and mineral, once they are not 
directly covered by the FSD. With this concern, the EFSA and the Scientific Committee of Food were 
requested by the EC to provide scientific opinions on assessing how to establish maximum levels of 
vitamins and mineral permitted in food supplements, as also additional opinions on nutrients other than 
these substances. Among these other substances are amino acids, enzymes, pre- and probiotics, essential 
fatty acids, botanicals and botanical extracts, and miscellaneous bioactive substances [7,34,43]. In June 
2006, the Directorate General Health and Consumer Protection has published a discussion paper on the 
establishment of maximum and minimum amounts of vitamins and minerals in foods where the issues to 
be considered in this exercise are identified; furthermore, all interested parties were invited to provide their 
view, which are currently in analysis [7,44]. 
Regarding to dietary supplements considered as medicinal products, including herbal medicinal products, 
a Committee for Herbal Medicinal Products, established at the EMA was created to establish Community 
monographs for THMP and further facilitate the registration and harmonization in this field. A draft list 
was then prepared taking into account the substances used in traditional medicine for a sufficiently long 
time to be considered safe under normal conditions of use. The referred list is present on the Commission 




6. Labelling of dietary supplements 
According to the FD&C Act and the respective amendments by DSHEA, in the USA, dietary supplements 
must carry on the label the name and the quantity of each ingredient or with respect to a proprietary blend 
of such ingredients, the total quantity of all ingredients in the blend. The label must also identify the product 
by using the term “dietary supplement”, which may be modified with the name of such an ingredient and, 
in cases where the supplement contains plants material, the labelling must identify the parts of the plant 
from which it was derived. Regarding to supplement listing on the nutrition labelling, a dietary supplement 
shall comply with some labelling requirements such as first listing the dietary ingredients that are present 
in the product in a significant amount and for which a recommendation for daily consumption has been 
established by the Secretary, and also list any other dietary ingredient present and identified as having no 
such recommendation. The listing if dietary ingredients shall include the quantity of each ingredient per 
serving and may include the source of the ingredient; the nutrition information shall immediately precede 
the ingredient information, except that no ingredient identified shall be required to be identified a second 
time. Moreover, the label of a dietary supplement or food product may contain one of three types of claims: 
health claim, nutrient content claim, or structure/function claim. Nonetheless, the claims may not explicitly 
or implicitly claim to prevent, treat, mitigate, cure, or diagnose a disease; it can claim a benefit related to a 
classical nutrient deficiency disease with disclosed prevalence in the US, characterize the documented 
mechanism by which a nutrient or dietary ingredient acts in the maintenance of such structure or function, 
or describe well-being from consumption of a nutrient or dietary ingredient. In cases where this is not 
respected and a dietary supplement label contain a disease claim, FDA treats the product as an unapproved 
drug and may take enforcement actions against the manufacturer or distributor. Among these actions, FDA 
can issue a warning letter, seize the product, seek criminal prosecution, or prohibit the sale of the product 
through an injunction [7,31,38] (Figure 4). 
In the EU, the labelling and the package leaflet of dietary supplements considered as medicinal products 
must respect Title V of the Directive 2001/83/EC. Accordingly, some particulars shall appear on the outer 
packaging or, where it does not apply, on the immediate packaging, such as “the name of the medicinal 
product followed by its strength and pharmaceutical form, and, if appropriate, whether it is intended for 
babies, children or adults”; “a statement of the active substances expressed qualitatively and quantitatively 
per dosage unit or according to the form of administration for a given volume or weight, using their common 
names”; “the pharmaceutical form and the contents by weight, by volume or by number of doses of the 
product”; “a list of those excipients known to have a recognized action or effect”; “the method of 
administration and, if necessary, the route of administration”; “a special warning that the medicinal product 
must be stored out of the reach and sight of children”; “a special warning, if this is necessary for the 
medicinal product”;  “the expiry date in clear terms (month/year)”; “special storage precautions, if any”; 
among many others. The Directive also contains recommendations on the labelling of products subject and 
not subject to prescription, stating that the National competent authorities must notify the Commission of 
non-prescription medicinal products which they judge to be at risk of falsification and may inform the 
Commission of medicinal products which they deem not to be at risk according to criteria also described in 
the Directive, and specifies how the Member States may proceed regarding to reimbursement purposes 
(Article 54a) [7,35]. 
The labelling requirements applied to dietary supplements considered as foodstuffs are described in the 
FSD, in accordance with the Article 5(1) of Directive 2000/13/EC, relating to the labelling, presentation 
and advertising of foodstuffs, whereby the name under which products covered by this Directive are sold 
shall be “food supplement”. Moreover, these supplements must not carry on the label, presentation and 
advertising the property of preventing, treating or curing a human disease, but should carry some particulars 
such as (i) “the names of the categories of nutrients or substances that characterize the product or an 
indication of the nature of those nutrients or substances”; 
(ii) “the portion of the product recommended for daily consumption”; (iii) “a warning not to exceed the 
stated recommended daily dose”; (iv) “a statement to the effect that food supplements should not be used 
as a substitute for a varied diet”; and (v) “a statement to the effect that the products should be stored out of 
the reach of young children”. Also, the label should not present any mention stating or implying that the 
appropriate quantities of nutrients cannot be provided by a balanced and varied diet, and the amount of 
those nutrients or substances with nutritional or physiological effect shall be declared in numerical form 
(expressed in the units specified in Annex II to FSD), per portion of the product as recommended for daily 
consumption. For vitamins and minerals, the amounts shall also be indicated in percentage of the reference 
values mentioned in the Annex to Directive 90/496/EEC, which may also be given in graphical form. In 
order to facilitate the efficient monitoring of food supplements, the person placing the product on the market 
may be required (by the Member State in which the product is placed on the market) to forward a model of 
the label used for the product to the competent authority [6,7,34,46,47]. Later, the general principles of this 
directive were complemented by the Regulation (EC) 1924/2006 that lay down specific provisions 
concerning the use of nutrition and health claims regarding foods to be delivered as such to the consumer 
[7,48] (Figure 4).  
 
7. Conclusion 
Dietary supplements are worldwide used for several purposes and its consumption is steeply increasing. 
Nevertheless, the safety and efficacy of such products can be compromised by the lack of specific regulatory 
legislation surrounding this subject. Indeed, there are many differences between the USA and EU legislation 
concerning dietary supplements and even among the different Member States of the EU, discrepancies can 
be found when it concerns the marketing of new products. In a general way, in the US, dietary supplements 
are considered as a food category and, therefore, are mainly regulated by the FDA that surveys their 
marketing and labelling requirements, through surveillance of products adverse events reports, regulations 
complying, and new dietary ingredients notifications, among others. On the other hand, considering that in 
the EU some dietary supplements fall into the scope of food and drug definition, they are often regulated 
as foodstuff or medicines depending on its composition, presentation, and function; thus, dietary 
supplements are principally regulated by the FSD or by the Directive 2001/83/EC (in accordance with the 
respective amendments), as appropriate. Nonetheless, according to the referred legislation, there are several 
improvements that need to be done because hitherto the attention has been mainly directed to food safety 
and claims of efficacy, but the remaining issues have been poorly explored. Further research could comprise 
relevant issues such as beneficial and harmful effects of the combined use of dietary supplements and 
chemical drugs, given that self-medication is also increasing and can result in undesirable consequences. 
Also, the competent authorities could explore the long-term safety of these products after being placed on 
the market, by assessing post-launch effectiveness and safety. To improve the correct utilization of dietary 
supplements, health technology assessment could be used on providing evidence about the most favourable 
supplements for each kind of treatment, elucidating the consumer about the cost-effectiveness and risk-
benefit ratio. 
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Figure 2. Overview of the legislation on dietary supplements in the EU. 
 
 
Figure 3. Marketing requirements for dietary supplements in the USA and the EU. 
 
 
Figure 4. Labelling specifications for dietary supplements in the USA and the EU. 
 
